Anti-Tumor Pharmacology
Total Page:16
File Type:pdf, Size:1020Kb
1078 Section 3: Anti-tumor pharmacology Doi: 10.1038/aps.2017.66 Wen-na SHI1, Shu-xiang CUI2, Zhi-yu SONG1, Shu-qing WANG1, Shi-yue SUN1, Xin-feng S3.1 YU1, Yu-hang ZHANG1, Zu-hua GAO3,*, Xian-jun QU1,* Synergistic effect of Astragalus flavonoids on breast cancer chemotherapeutic agent 1Department of Pharmacology, School of Basic Medical Sciences, Capital Medical cyclophosphamide based on the regulation of immune function University, Beijing, China; 2Beijing Key Laboratory of Environmental Toxicology, Jing WANG, Xiao LI, Yan-shuang QI, Jia-hui NIE, Xue-mei QIN* Department of Toxicology and Sanitary Chemistry, School of Public Health, Capital Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan Medical University, Beijing, China; 3Department of Pathology, McGill University, 030006, China Montreal, Quebec, Canada *To whom correspondence should be addressed. *To whom correspondence should be addressed. E-mail: [email protected] E-mail: [email protected] The present study aimed to observe the synergistic effect of Astragalus flavonoids The resistance mechanisms that limit the efficacy of retinoid therapy in cancer are (TFA) on breast cancer chemotherapeutic agent cyclophosphamide (CTX) and its poorly understood. Sphingosine kinase 2 (SphK2) is a highly conserved enzyme that effect on immunologic function. 4T1 breast cancer bearing mice were established is mainly located in the nucleus and endoplasmic reticulum. Unlike well-studied and then randomly into control group, model group, CTX group (80 mg/kg), sphingosine kinase 1 (SphK1) located in the cytosol, little has yet understood the CTX (80 mg/kg) combined with TFA (6 mg/kg) group and TFA group (6 mg/ functions of SphK2. Here we show that SphK2 over-expression contributes to the kg). After 3 weeks of different treatments, tumor inhibition rates were measured; resistance of all-trans retinoic acid (ATRA) therapy in colon cancer through rapid subpopulation of the splenic lymphocytes and marrow derived suppressor cells degradation of cytoplasmic retinoid X receptor α (RXRα) by lysine 48 (K48)- and (MDSCs) in circulating blood were detected by flow cytometry. Compared with lysine 63 (K63)-based polyubiquitination. Human colonic adenocarcinoma HCT- model group, both CTX and CTX-TFA can significantly inhibit tumor growth with 116 cells transfected with SphK2 (HCT-116Sphk2 cells) demonstrate resistance to inhibition rate of 55.61% (P<0.05) and 70.91% (P<0.01), respectively. However, ATRA therapy as determined by in vitro and in vivo assays. Sphk2 over-expression compared to CTX group, CTX-TFA group showed a higher inhibition rate increases the ATRA-induced nuclear RXRα export to cytoplasm and then rapidly (P<0.05). CTX-TFA group showed an increased percentage of splenic CD3+, CD4+ degrades RXRα through the poly-ubiquitination pathway. We further show that T and CD8+ T lymphocytes (P<0.05, P<0.01) and decreased percentage of MDSCs Sphk2 activates the ubiquitin-proteasome system through the signal mechanisms (CD11b+Ly6Chi) (P<0.05, P<0.01), whereas the percentage of CD19+ cells remained of (1) K48-linked proteosomal degradation and (2) K63-linked ubiquitin-dependent unchanged. TFA could enhance the anti-tumor effect of CTX and the synergistic autophagic degradation. These results provide new insights into the biological effect probably result from improving tumor immune-suppression via increasing functions of Sphk2 and the molecular mechanisms that underlie the Sphk2- the percentage of CD3+, CD4+ T and CD8+ T lymphocytes and down-regulating the mediated resistance to retinoid therapy. percentage of MDSCs. Keywords: sphingosine kinase 2 (SphK2); retinoid therapy resistance; cytoplasmic Keywords: Astragalus flavonoids; breast cancer; cyclophosphamide; immune RXRα; polyubiquitination; rapid degradation; lysine 48 (K48); lysine 63 (K63) function Acknowledgements: This work was supported by grants from National Natural Acknowledgements: This work was supported by grants from Science and Science Foundation of China (No 81373436, 81373435 and 91229113) and the Beijing Technology Innovation Team of Shanxi Province (No 201605D131045-18) and Science Foundation (No 7142017). We thank the Research Institute of the McGill Key laboratory of Effective Substances Research and Utilization in TCM of Shanxi University Health Centre for their financial support. province (No 201605D111004). S3.4 S3.2 Chemoprevention of intestinal tumorigenesis by the natural dietary flavonoid Anti-Warburg effect elicited by cAMP-PGC1α pathway drives differentiation of myricetin and its derivative in APCMin/+ mice glioblastoma cells into astrocytes Ye LI1, Shi-yue SUN1, Zhi-yu SONG1, Shu-qing WANG1, Zu-hua GAO2, Xian-jun QU1, Shu- Wen-bo ZHU1, Fan XING1, Jia-luo MAI1, Jia-yu GU1, Xin-cheng LIU1, Wan-jun LU1, Guang- xiang CUI3,* mei YAN1,* 1Department of Pharmacology, Capital Medical University School of Basic Medical 1Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Sciences, Beijing, China; 2Department of Toxicology and Sanitary Chemistry, School Gangzhou 510080, China of Public Health, Capital Medical University, Beijing, China; 3Department of Pathology, *To whom correspondence should be addressed. McGill University, Montreal, Quebec, Canada E-mail: [email protected] *To whom correspondence should be addressed. Glioblastoma (GBM) is among the most aggressive of human cancers. Although E-mail: [email protected] differentiation therapy has been proposed as a potential approach to treat GBM, Myricetin is a natural dietary flavonoid compound. We evaluated the efficacy the mechanisms of induced differentiation remain poorly defined. Here, we of myricetin and its derivative against intestinal tumorigenesis in adenomatous established an induced differentiation model of GBM using cAMP activators, polyposis coli multiple intestinal neoplasia (APCMin/+) mice. Myricetin was given which specifically directed GBM into astroglia. Next, transcriptomic and proteomic orally once a day for 12 consecutive weeks. APCMin/+ mice fed with myricetin analyses uncovered oxidative phosphorylation and mitochondrial biogenesis were developed fewer and smaller polyps without any adverse effects. Histopathological involved in induced differentiation of GBM. Further investigation showed dbcAMP analysis showed a decreased number of dysplastic cells and degree of dysplasia reversed the Warburg effect evidenced by increase in oxygen consumption and in each polyp. Immunohistochemical and Western blot analysis revealed reduction of lactate production. Stimulated mitochondrial biogenesis downstream that myricetin selectively inhibits cell proliferation and induces apoptosis in of CREB/PGC1α pathway triggered metabolic shift and differentiation. Blocking adenomatous polyps. The effects of myricetin were associated with a modulation mitochondrial biogenesis by mdivi1 or silencing PGC1α abrogated differentiation, the GSK-3β and Wnt/β-catenin pathways. ELISA analysis showed a reduced reversely overexpression of PGC1α elicited differentiation. In GBM xenograft concentration of pro-inflammatory cytokines IL-1β, IL-6, TNF-α, and PGE2 in the models and patient-derived GBM samples, cAMP activators also induced tumor adenomatous polyps and blood, which were elevated in APCMin/+ mice. The effect of growth inhibition and differentiation. This study shows mitochondrial biogenesis myricetin treatment was most prominent in the adenomatous polyps originating in and metabolic switch to oxidative phosphorylation drive the differentiation process the colon. Further study showed that myricetin down-regulates the phosphorylated of tumor cells. p38 MAPK/Akt/mTOR signaling pathways, which may be the mechanisms for Keywords: differentiation therapy; metabolic reprogramming; Warburg effect; PGC- the inhibition of adenomatous polyps by myricetin. Taken together, our data 1 alpha; mitochondrial biogenesis show that myricetin inhibits intestinal tumorigenesis through a collection of Acknowledgements: This work was supported by grants from the the National biological activities. Given these results, we suggest that myricetin could be used Natural Science Foundation of China (No 81673447), the Natural Science preventatively to reduce the risk of developing colon cancers. Foundation of Guangdong Province, China (No 2014A030313156) and the specific Keywords: myricetin; APCMin/+ mouse model; intestinal adenomatous polyps; project of science and technology of Guangzhou (No 201607010396). Wnt/β-catenin pathway; chronic inflammation; p38 MAPK/Akt/mTOR signaling pathways S3.3 Acknowledgements: This work was supported by grants from the National Natural Over-expression of SphK2 contributes to ATRA resistance in colon cancer through Science Foundation of China (No 81373435). rapid degradation of cytoplasmic RXRα by K48/K63-linked polyubiquitination Acta Pharmacologica Sinica (2017) Section 3: Anti-tumor pharmacology 1079 S3.5 Development Plan of Shandong Province, China (No 2014WS0486). The application of "Warburg effect" in chemosensitization–a case report Yong-ping LIU*, Ya-ping ZHANG, Xi-bao MAO, Qiu-feng QI, Ming ZHU, Yang LING S3.7 Department of Oncology Medicine, Changzhou Tumor Hospital Affiliated to Soochou Quantitative proteomics of transgenic prostate cancer mice reveals that PDGF-B University, Honghe Road No.68, Xinbei Area, Changzhou 213002, China regulatory network plays a key role in prostate cancer progression *To whom correspondence should be addressed. Dan WANG, Jia MI, Chun-hua YANG, Shu-ping ZHANG, Bin WANG,